LAUSR

Key Points Question Are commonly used treatments for metastatic castration-resistant prostate cancer (mCRPC) associated with a decline in cognitive function in older men? Findings This cohort study followed up 198 men aged 65 years or older with mCRPC treated with docetaxel, abiraterone acetate, enzalutamide, or radium Ra 223 dichloride. More than 90% of patients had stable or only slightly reduced cognition (measured using the Trail Making Test part A, the Trail Making Test part B, and the Montreal Cognitive Assessment), with minimal differences among treatments. Meaning These findings suggest that most older men do not experience significant cognitive decline while undergoing treatment for mCRPC regardless of the treatment used.